Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit.
Antimalarials are arguably the best modality currently available for treating patients with cutaneous lupus erythematosus (LE). Although antimalarials have been used for decades in treating cutaneous LE, the precise mechanisms by which they provide therapeutic benefit are not well defined. The putative mechanisms by which antimalarials might provide therapeutic benefit to patients with cutaneous LE include a number of interrelated anti-inflammatory and immunosuppressive effects that include photoprotection, lysosomal stabilization, suppression of antigen presentation, and inhibition of prostaglandin and cytokine synthesis. If we had a more precise understanding of how antimalarials provide therapeutic benefit in cutaneous LE we might gain better insight into the pathogenic mechanisms of LE and ways of developing better therapies for afflicted patients.
Wozniacka
A
A
Department of Dermatology, Medical University of Lodz, Krzemieniecka, Poland.
Carter
A
A
McCauliffe
D P
DP
D000962:Antimalarials / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D005947:Glucose; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008247:Lysosomes / Q000187:drug effects; D011453:Prostaglandins / Q000096:biosynthesis; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology
D000962:Antimalarials; D011453:Prostaglandins; D005947:Glucose